查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1309269

毛细胞白血病市场：规模 - 按治疗类型、疗法、产品类型、药物类别、给药途径、最终用户、区域展望、竞争策略、到 2033 年的细分市场预测

Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 250 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到2033年，全球毛细胞白血病市场规模将达到1亿美元，复合年增长率为4.89%。

该报告考察了全球毛细胞白血病市场，并按治疗类型、疗法、产品类型、药物类别、给药途径、最终用户、地区和进入市场的参与者概况提供了市场概述以及趋势。

目录

第1章简介

第2章调查方法

第3章执行摘要

第4章市场动态

  • 驱动因素、限制因素、机会和挑战分析
  • COVID-19 对全球毛细胞白血病市场的影响

第5章市场变量与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力
  • 热图分析

第6章竞争格局

第7章全球毛细胞白血病市场，按治疗类型（百万美元）

  • 2023-2033年全球毛细胞白血病市场价值份额及按治疗类型预测
  • 药物治疗
  • 外科手术

第8章全球毛细胞白血病市场，按治疗分类（百万美元）

  • 2023-2033 年全球毛细胞白血病市场价值份额及预测（按治疗方法）
  • 化学处理
  • 免疫疗法
  • 靶向治疗

第9章全球毛细胞白血病市场，按产品类型（百万美元）

  • 2023-2033年全球毛细胞白血病市场价值份额及产品类型预测
  • 胶囊
  • 肠外用药
  • 药片
  • 其他的

第10章全球毛细胞白血病市场，按药物类别（百万美元）

  • 2023-2033 年全球毛细胞白血病市场价值份额及预测（按药物类别）
  • 美女蒂凡
  • 贝伐珠单抗
  • 卡莫司汀
  • 依维莫司
  • 洛莫司汀
  • 替莫唑胺
  • 其他的

第11章全球毛细胞白血病市场，按给药途径划分（百万美元）

  • 2023-2033 年全球毛细胞白血病市场价值份额及预测（按给药途径）
  • 口服
  • 注射用
  • 其他的

第12章全球毛细胞白血病市场，按最终用户划分（百万美元）

  • 2023-2033 年全球毛细胞白血病市场价值份额及预测（按最终用户）
  • 家庭护理
  • 医院
  • 专科诊所
  • 其他的

第13章2019-2033年全球毛细胞白血病市场预测（百万美元）

第14章全球毛细胞白血病市场，按治疗类型，2019-2033（百万美元）

第15章全球毛细胞白血病市场（按治疗方法），2019-2033 年（百万美元）

第16章全球毛细胞白血病市场，按产品类型，2019-2033（百万美元）

第17章全球毛细胞白血病市场，按药物类别，2019-2033（百万美元）

第18章全球毛细胞白血病市场，按给药途径划分，2019-2033 年（百万美元）

第19章全球毛细胞白血病市场，按最终用户划分，2019-2033 年（百万美元）

第20章全球毛细胞白血病市场，按地区，2019-2033（百万美元）

  • 全球毛细胞白血病市场规模及按地区分類的市场份额（2019-2026）
  • 全球毛细胞白血病市场规模及按地区分類的市场份额（2027-2033）
  • 亚太地区
  • 欧洲
  • 中东/非洲
  • 北美
  • 拉美

第二十一章 公司简介

  • AbbVie Inc
  • Amgen Inc
  • Astellas Pharma Inc
  • Astex Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biogenomics Limited
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • Fresenius SE and Co. KGaA
  • GlaxoSmithKline plc
  • Hoffmann-La Roche
  • Janssen Global Services
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Co.
  • Takeda Pharmaceutical Company Limited
  • 其他的

第22章 缩写表

第23章 参考链接

第24章结论

第25章 调查范围

简介目录
Product Code: HLCA2348

Hairy Cell Leukemia Market Overview

According to SPER market research, 'Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Hairy Cell Leukemia Market is predicted to reach USD 0.10 billion by 2033 with a CAGR of 4.89%.

Hairy cell leukaemia is a rare type of cancer, in which the bone marrow causes lymphocytes to develop out of control. The name "hairy cell leukaemia" refers to a characteristic of the disease's morphology. In hairy cell leukaemia, the extra B cells grow aberrant extensions and have a hairy appearance. The quantity of healthy white blood cells, red blood cells, and platelets in the body decrease noticeably as the number of leukaemia cells increases. Usually, the illness takes time to develop without any noticeable symptoms.

Healthcare services were affected as a result of the COVID-19 pandemic, reducing access to basic care, including diagnosis and treatment. Delays in the clinical trials for the new treatments have an impact on therapy developments. Disruptions in the supply chain made it difficult to manage treatment plans and obtain the necessary drugs. There were fewer in-person visits and monitoring sessions, which increased reliance on online consultations. Challenges with affordability and reimbursement arose as a result of financial issues.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User

Regions covered Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Astex Therapeutics, AstraZeneca, Bayer AG, Biogenomics Limited, Bristol Myers Squibb Company, Fresenius SE and Co. KGaA, GlaxoSmithKline plc, Hoffmann-La Roche, Janssen Global Services,

Hairy Cell Leukemia Market Key Segments Covered

By Therapy Type: Based on the Therapy Type, Global Hairy Cell Leukemia Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy.

By Product Type: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Capsules, Parenterals, Tablets, Others.

By End User: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Homecare, Hospitals, Specialty Clinics, Others.

By Region: This research also includes data for Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Hairy Cell Leukemia Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Hairy Cell Leukemia Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hairy Cell Leukemia Market

7. Global Hairy Cell Leukemia Market, By Treatment Type (USD Million)

  • 7.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Treatment Type, 2023-2033
  • 7.2. Medication
  • 7.3. Surgery

8. Global Hairy Cell Leukemia Market, By Therapy Type (USD Million)

  • 8.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Therapy Type, 2023-2033
  • 8.2. Chemotherapy
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy

9. Global Hairy Cell Leukemia Market, By Product Type (USD Million)

  • 9.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Product Type, 2023-2033
  • 9.2. Capsules
  • 9.3. Parenterals
  • 9.4. Tablets
  • 9.5. Others

10. Global Hairy Cell Leukemia Market, By Drug Class (USD Million)

  • 10.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Drug Class, 2023-2033
  • 10.2. Belzutifan
  • 10.3. Bevacizumab
  • 10.4. Carmustine
  • 10.5. Everolimus
  • 10.6. Lomustine
  • 10.7. Temozolomide
  • 10.8. Others

11. Global Hairy Cell Leukemia Market, By Route of Administration (USD Million)

  • 11.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Route of Administration, 2023-2033
  • 11.2. Oral
  • 11.3. Parenteral
  • 11.4. Others

12. Global Hairy Cell Leukemia Market, By End User (USD Million)

  • 12.1. Global Hairy Cell Leukemia Market Value Share and Forecast, End User, 2023-2033
  • 12.2. Homecare
  • 12.3. Hospitals
  • 12.4. Specialty Clinics
  • 12.5. Others

13. Global Hairy Cell Leukemia Market Forecast, 2019-2033 (USD Million)

  • 13.1. Global Hairy Cell Leukemia Market Size and Market Share

14. Global Hairy Cell Leukemia Market, By Treatment Type, 2019-2033 (USD Million)

  • 14.1. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2019-2026)
  • 14.2. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2027-2033)

15. Global Hairy Cell Leukemia Market, By Therapy Type, 2019-2033 (USD Million)

  • 15.1. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2019-2026)
  • 15.2. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2027-2033)

16. Global Hairy Cell Leukemia Market, By Product Type, 2019-2033 (USD Million)

  • 16.1. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2019-2026)
  • 16.2. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2027-2033)

17. Global Hairy Cell Leukemia Market, By Drug Class, 2019-2033 (USD Million)

  • 17.1. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2019-2026)
  • 17.2. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2027-2033)

18. Global Hairy Cell Leukemia Market, By Route of Administration, 2019-2033 (USD Million)

  • 18.1. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2019-2026)
  • 18.2. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2027-2033)

19. Global Hairy Cell Leukemia Market, By End User, 2019-2033 (USD Million)

  • 19.1. Global Hairy Cell Leukemia Market Size and Market Share By End User (2019-2026)
  • 19.2. Global Hairy Cell Leukemia Market Size and Market Share By End User (2027-2033)

20. Global Hairy Cell Leukemia Market, By Region, 2019-2033 (USD Million)

  • 20.1. Global Hairy Cell Leukemia Market Size and Market Share By Region (2019-2026)
  • 20.2. Global Hairy Cell Leukemia Market Size and Market Share By Region (2027-2033)
  • 20.3. Asia-Pacific
    • 20.3.1. Australia
    • 20.3.2. China
    • 20.3.3. India
    • 20.3.4. Japan
    • 20.3.5. South Korea
    • 20.3.6. Rest of Asia-Pacific
  • 20.4. Europe
    • 20.4.1. France
    • 20.4.2. Germany
    • 20.4.3. Italy
    • 20.4.4. Spain
    • 20.4.5. United Kingdom
    • 20.4.6. Rest of Europe
  • 20.5. Middle East and Africa
    • 20.5.1. Kingdom of Saudi Arabia
    • 20.5.2. United Arab Emirates
    • 20.5.3. Rest of Middle East & Africa
  • 20.6. North America
    • 20.6.1. Canada
    • 20.6.2. Mexico
    • 20.6.3. United States
  • 20.7. Latin America
    • 20.7.1. Argentina
    • 20.7.2. Brazil
    • 20.7.3. Rest of Latin America

21. Company Profile

  • 21.1. AbbVie Inc,
    • 21.1.1. Company details
    • 21.1.2. Financial outlook
    • 21.1.3. Product summary
    • 21.1.4. Recent developments
  • 21.2. Amgen Inc
    • 21.2.1. Company details
    • 21.2.2. Financial outlook
    • 21.2.3. Product summary
    • 21.2.4. Recent developments
  • 21.3. Astellas Pharma Inc
    • 21.3.1. Company details
    • 21.3.2. Financial outlook
    • 21.3.3. Product summary
    • 21.3.4. Recent developments
  • 21.4. Astex Therapeutics
    • 21.4.1. Company details
    • 21.4.2. Financial outlook
    • 21.4.3. Product summary
    • 21.4.4. Recent developments
  • 21.5. AstraZeneca
    • 21.5.1. Company details
    • 21.5.2. Financial outlook
    • 21.5.3. Product summary
    • 21.5.4. Recent developments
  • 21.6. Bayer AG
    • 21.6.1. Company details
    • 21.6.2. Financial outlook
    • 21.6.3. Product summary
    • 21.6.4. Recent developments
  • 21.7. Biogenomics Limited
    • 21.7.1. Company details
    • 21.7.2. Financial outlook
    • 21.7.3. Product summary
    • 21.7.4. Recent developments
  • 21.8. Bristol Myers Squibb Company
    • 21.8.1. Company details
    • 21.8.2. Financial outlook
    • 21.8.3. Product summary
    • 21.8.4. Recent developments
  • 21.9. Celgene Corporation
    • 21.9.1. Company details
    • 21.9.2. Financial outlook
    • 21.9.3. Product summary
    • 21.9.4. Recent developments
  • 21.10. Daiichi Sankyo Company Limited
    • 21.10.1. Company details
    • 21.10.2. Financial outlook
    • 21.10.3. Product summary
    • 21.10.4. Recent developments
  • 21.11. Dr. Reddy's Laboratories Ltd
    • 21.11.1. Company details
    • 21.11.2. Financial outlook
    • 21.11.3. Product summary
    • 21.11.4. Recent developments
  • 21.12. Eli Lilly and Company
    • 21.12.1. Company details
    • 21.12.2. Financial outlook
    • 21.12.3. Product summary
    • 21.12.4. Recent developments
  • 21.13. Emcure Pharmaceuticals
    • 21.13.1. Company details
    • 21.13.2. Financial outlook
    • 21.13.3. Product summary
    • 21.13.4. Recent developments
  • 21.14. Fresenius SE and Co. KGaA
    • 21.14.1. Company details
    • 21.14.2. Financial outlook
    • 21.14.3. Product summary
    • 21.14.4. Recent developments
  • 21.15. GlaxoSmithKline plc
    • 21.15.1. Company details
    • 21.15.2. Financial outlook
    • 21.15.3. Product summary
    • 21.15.4. Recent developments
  • 21.16. Hoffmann-La Roche
    • 21.16.1. Company details
    • 21.16.2. Financial outlook
    • 21.16.3. Product summary
    • 21.16.4. Recent developments
  • 21.17. Janssen Global Services
    • 21.17.1. Company details
    • 21.17.2. Financial outlook
    • 21.17.3. Product summary
    • 21.17.4. Recent developments
  • 21.18. Johnson & Johnson Services, Inc.
    • 21.18.1. Company details
    • 21.18.2. Financial outlook
    • 21.18.3. Product summary
    • 21.18.4. Recent developments
  • 21.19. Merck & Co., Inc
    • 21.19.1. Company details
    • 21.19.2. Financial outlook
    • 21.19.3. Product summary
    • 21.19.4. Recent developments
  • 21.20. Novartis AG
    • 21.20.1. Company details
    • 21.20.2. Financial outlook
    • 21.20.3. Product summary
    • 21.20.4. Recent developments
  • 21.21. Pfizer Inc.
    • 21.21.1. Company details
    • 21.21.2. Financial outlook
    • 21.21.3. Product summary
    • 21.21.4. Recent developments
  • 21.22. Sumitomo Dainippon Pharma Co.,
    • 21.22.1. Company details
    • 21.22.2. Financial outlook
    • 21.22.3. Product summary
    • 21.22.4. Recent developments
  • 21.23. Takeda Pharmaceutical Company Limited
    • 21.23.1. Company details
    • 21.23.2. Financial outlook
    • 21.23.3. Product summary
    • 21.23.4. Recent developments
  • 21.24. Others

22. List of Abbreviations

23. Reference Links

24. Conclusion

25. Research Scope